News >

Galeterone Prostate Cancer Trial Closes as PFS Rates Miss Mark

Tony Berberabe, MPH @OncBiz_Wiz
Published: Tuesday, Jul 26, 2016

The pivotal phase III prostate cancer trial ARMOR 3-SV will be discontinued based on recommendations made by the trial’s independent data monitoring committee (DMC), according to the manufacturer Tokai Pharmaceuticals. The DMC concluded that ARMOR 3-SV would unlikely meet its primary endpoint of demonstrating improved radiographic progression-free survival (PFS) based on its review of all safety and efficacy data. Top-line data from the trial is not expected until next year.

1. NIH Clinical Trials Registry. NCT01709734

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication